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Neoantimycins are anticancer compounds of 15-membered
ring antimycin-typedepsipeptides. They are biosynthesizedby a
hybridmultimodular protein complex of nonribosomal peptide
synthetase (NRPS) and polyketide synthase (PKS), typically
from the starting precursor 3-formamidosalicylate. Examining
fermentation extracts of Streptomyces conglobatus, here we dis-
covered four new neoantimycin analogs, unantimycins B–E, in
which 3-formamidosalicylates are replaced by an unusual 3-hy-
droxybenzoate (3-HBA) moiety. Unantimycins B–E exhibited
levels of anticancer activities similar to those of the chemother-
apeutic drug cisplatin in human lung cancer, colorectal cancer,
and melanoma cells. Notably, they mostly displayed no signifi-
cant toxicity toward noncancerous cells, unlike the serious tox-
icities generally reported for antimycin-type natural products.
Using site-directed mutagenesis and heterologous expression,
we found that unantimycin productions are correlated with the
activity of a chorismatase homolog, thenat-hyg5 gene, froma type
I PKS gene cluster. Biochemical analysis confirmed that the cata-
lytic activity of Nat-hyg5 generates 3-HBA from chorismate.
Finally, we achieved selective production of unantimycins B andC
by engineering a chassis host. On the basis of these findings, we
propose that unantimycin biosynthesis is directed by the neoanti-
mycin-producing NRPS–PKS complex and initiated with the
starter unit of 3-HBA. The elucidation of the biosynthetic unanti-
mycinpathway reportedhere paves theway to improve the yield of
these compounds for evaluation in oncotherapeutic applications.
Antimycin-type depsipeptides are a family of natural prod-
ucts with various important biological activities such as anti-
cancer, antifungal, and anti-inflammatory activities (1). They
share a 9-, 12-, 15-, or 18-membered macrolide ring with an
amide linkage to a conserved 3-formamidosalicylate (3-FAS)3
moiety. In particular, neoantimycins (NATs) feature a
15-membered tetralactone core conjugated with a 3-FAS moi-
ety. The twelve NAT entities previously isolated from actino-
mycete species differ structurally through varying size of alkyl
side chains at the C4 and C9 positions, either hydroxyl or
ketone at C1, and the substitution of the conserved 3-FAS with
a 3-amidosalicylate, benzoyl, or 3-hydroxybenzoyl (1) (Fig. 1).
The majority of NATs show excellent anticancer activities, e.g.
NAT-A, -F, and -H have IC50 values of 0.1–0.8 M against
human ovarian cancer cells (2) and IC50 values of 0.2–0.6 M
against human colon cancer cells (3), respectively. Inmolecular
pharmacological studies, theNATanalogs prunustatinA, JBIR-
04, and JBIR-05 have been shown to down-regulate GRP-78, a
molecular chaperone contributing to chemotherapy resistance
(4, 5). Moreover, the 3-FAS moiety in NATs was verified as a
potent pharmacophore of inhibitory activity toward oncogenic
K-Ras (3).
The biosynthesis of antimycin-type depsipeptides is accom-
plished by a hybrid complex of NRPS and PKS multimodular
proteins, which acts as an assembly line and is typically initiated
with the starter unit of 3-FAS (1, 6). The 3-FAS precursor is
supplied by a biosynthetic pathway encoded by a gene cassette
conservatively associated with the biosynthetic gene clusters
(BGCs) of antimycin-type depsipeptides (7, 8). The macrolide
skeleton of NATs is generated from a NRPS-PKS multienzyme
assembly line by loading the starter unit of 3-FAS and the elon-
gation units of one L-threonine, three -keto acids, and one
malonic acid (2, 9, 10). The offloaded 15-membered macrocy-
clic rings are converted into the final NATs via C1 hydroxyl-
ation conducted by a NAD(P)H-dependent ketoreductase (2).
As the representative moiety in antimycin-type depsipep-
tides, 3-FAS has been shown to be essential to the anticancer
activities of NAT derivatives (3, 11). The 3-FAS group is, how-
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ever, also known to be mostly responsible for the tight binding
of antimycin to the quinone reduction site of the cytochrome
bc1 complex, resulting in inhibition of the mitochondrial respi-
ratory chain (12). Therefore the 3-FAS group could be prob-
lematic in development of this family of molecules toward anti-
tumor application.
During purification of NATs from the fermentation extract
of Streptomyces conglobatus, we have discovered four newNAT
analogs, unantimycins B–E (1–4), which are derivatives of the
reported unantimycin A (13) bearing an alternative side chain
of 3-hydroxybenzoate (3-HBA) instead of 3-FAS (Fig. 2). Sur-
prisingly, despite replacement of the 3-FAS pharmacophore,
1–4 still exhibited similar levels of anticancer activity com-
pared with cisplatin. Moreover, they mostly presented no obvi-
ous toxicities to normal cells. The promising anticancer activi-
ties and the obscure biosynthetic origin of unantimycins
prompted us to investigate further the biosynthetic pathway. It
has been documented that 3-HBA generated by chorismatase
from chorismate can be recruited as a starting precursor in
the biosynthesis of polyketides BC325, cuevaene, and xan-
thomonadin (14–17) or as a donor group in the late modifica-
tion stage of terpenoid brasilicardin biosynthesis (18) (Fig. 2).
With the information, we did genomicmining of S. conglobatus
and discovered a unique candidate FkbO/Hyg5-type chorisma-
tase gene, nat-hyg5, located in an unknown type-I PKS BGC.
Inactivation ofnat-hyg5 by specificmutation abolished the pro-
duction of 1-4 in the mutant strain, and introduction of the
gene into the NAT heterologous expression made 1-4 pro-
duced as new components in the system. The recombinant pro-
tein of Nat-hyg5 was then demonstrated to have the catalytic
ability to produce 3-HBA efficiently from chorismate over a
broad pH range. These data strongly support a mechanism in
which Nat-hyg5 uses chorismate, the end product of shikimate
pathway, to produce 3-HBA as an alternative starter unit in
NAT biosynthesis to produce 1-4. The discovery of four new
NAT analogs with encouraging potential in anticancer activi-
ties and elucidation of their biosynthesis will now allow rational
bioengineering of the host strain to improve the production of
these analogs.
Results and discussion
Discovery and structural elucidation of 1–4
Compounds 1-4 were originally discovered from S. conglo-
batus, which produces the macrodiolide polyketide congloba-
tin as the main product (19). To simplify the purification pro-
cess, 1–4 were isolated from the fermentation extract of RJ2, a
mutant strain losing conglobatin production (see “Materials
and methods”). To isolate NAT derivatives, a 24-liter fermen-
tation broth was extracted with ethyl acetate, and the extract
was purified by consecutive chromatographic fractionation
to produce compounds 1 (16.0 mg), 2 (3.6 mg), 3 (3.0 mg), and
4 (0.6 mg) as white amorphous solid. The molecular formulae of
1–4wereestablishedasC35H43NO11,C35H45NO11,C34H41NO11,
and C34H43NO11, respectively, based on HR-ESI–MS analysis
(Table S2).
According to the 1D and 2D NMR (supporting text SII, Figs.
S1, S11–S14, and Tables S4–S7), the structures of compounds
1–4were elucidated as a 15-membered tetraester ring attached
with an acylamino-bounded 3-hydroxybenzoate (3-HBA) moi-
ety and a C2 monosubstituted benzene ring, bearing a C1
ketone for 1 and 3 and a C1 hydroxy for 2 and 4 (Fig. 2). 3 or 4
differ from1 or2 atC32 by having amethyl in the former and an
ethyl in the latter (Fig. 2). The structures of 1–4were also con-
firmed byHR-MS/MS analysis (supporting text SII, Fig. S2, and
Table S3). Considering the structural similarities of 1–4 to the
documented unantimycin A (13), bearing C4-methyl in con-
trast to C4-isopropyl of the formers, compounds 1–4were des-
ignated as unantimycin B to E, respectively.
Anticancer activity evaluation of 1–4
Because the 3-FASmoiety has been proposed to be the phar-
macophore of anticancer activities in NATs (3, 11), we wished
to know whether compounds 1–4 with the alternative 3-HBA
moiety, instead of 3-FAS, would retain anticancer activities.
The carcinoma cell lines of human lung (PC9), colon (Sw620),
and melanoma (A375) were firstly selected to evaluate the
activities of them, using as positive control the chemotherapeu-
tic drug cisplatin. In the bioactivity assay, 1–4 exhibited con-
siderable anticancer activities with IC50 values 1.6–8.2 M,
comparable with the IC50 of 1.1–6.3 M detected for cisplatin
(Table 1). This is consistentwith the activities previously shown
for unantimycin A, which structurally differs from 1 at the C4
alkyl group andwhich has shownmoderate cytotoxicity (IC50
10 M) against human cervix epidermoid carcinoma, promy-
elocytic leukemia, and sarcoma cell lines (13). Notably, in addi-
tion to the exception of 3 showing IC50 8.5 M to 16HBE cells,
1–4 generally displayed no obvious toxicity (IC50  31.9 M)
toward the related normal cells, in contrast to the IC50 of 2.7–
Figure 1. The structures of neoantimycin derivatives isolated from actinomycete species.
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4.6 M detected for cisplatin (Table 1). Further work will be
required to establish convincingly that the apparently selective
anticancer activities of 1–4 are endowed by the absence of
binding to the quinone reduction site of the cytochrome bc1
complex, whichmakes antimycin A lethal to themitochondrial
respiratory chain (12, 20). Moreover, the broad-spectrum anti-
cancer activities of 1–4 were evaluated by using six other car-
cinoma cell lines (Table S9). Except for displaying the IC50 of
2.3–7.7 M toward another lung cancer cells A549, these com-
pounds have relatively weak inhibitory effect on other five cell
lines such as colorectal cancer cells HT29 (14.9–19.4M), ileo-
cecal cancer cellsHCT-8 (9.0–17.9M), gastric carcinoma cells
SGC7901 (6.6–11.9 M), liver carcinoma cells HepG2 (13.4–
18.3 M), and cervical cancer cells HeLa (15.3–23.6 M).
Inactivation of nat-hyg5 gene by site-directedmutation
The attachment of 3-HBA moiety in compounds 1-4 sug-
gests that the PKS-NRPS assembly line of NAT biosynthesis
could accept 3-HBA, instead of 3-FAS, as a starter unit. It is
reported that 3-HBA can be generated by CH-Hyg5/CH-II type
chorismatase/3-hydroxybenzoate synthase from chorismate, a
product of the shikimate pathway (14, 21, 22). However, no
homolog of chorismatase was found within or at the boundary
of nat BGC (Table S8). We therefore conducted genome min-
ing of S. conglobatus screening with the sequence of Hyg5
derived from Streptomyces hygroscopicus, which has been veri-
fied as a CH-Hyg5 type chorismatase producing 3-HBA as the
starter unit in the biosynthesis of the rapamycin analog BC325
(14). Interestingly a single candidate gene nat-hyg5 with a 51%
identity (protein sequence) to Hyg5 was discovered, located in
an unknown type-I PKS BGC (GenBankTM accession no.
MN158725), in which a carboxylic acid ligase domain at the N
terminus of a PKS protein (similar to the startingmodule of rapa-
mycin or FK506 biosynthesis (23)) is likely to load a 3-HBA as
starter unit to initiate a polyketide assembly (Fig. S4). We thus
postulated that Nat-hyg5 could produce the 3-HBA as an alterna-
tive starter unit in NAT biosynthesis to produce 1-4 (Fig. 3).
To identify a possible role for the nat-hyg5 gene in the pro-
duction of 1-4, we first aimed to inactivate the gene by specific
mutation. According to the verified catalysis mechanism for
Hyg5, the essential acidic active site residueGlu-334 protonates
themethylene group in chorismate to initiate an intramolecular
nucleophilic attack and form an arene oxide intermediate,
which then undergoes a hydrogen-shift to produce 3-HBA and
pyruvate (21). Protein sequence alignment revealed Glu-325 as
the residue of Nat-hyg5 corresponding to the active site Glu-
334 in Hyg5 (Fig. S6). The active site mutation E325Qwas then
introduced into thenat-hyg5 gene in the chromosomeof S. con-
Figure 2. The structures of the natural products requiring 3-HBA as a building block in their biosynthetic pathways.
Table 1
The cytotoxic activities (IC50) of 1–4
The values shown are the means S.D. of triplicate determinations.
PC9a 16HBEb Sw620c NCM460d A375e HaCaTf
M M M M M M
1 2.44 0.19 98.4 1.9 1.62 0.32 65.5 1.5 5.73 0.20 75.8 0.5
2 2.80 0.07 31.9 0.8 4.52 0.11 100 5.05 0.48 100
3 3.50 0.85 8.47 0.12 8.19 0.55 100 4.84 0.01 100
4 4.47 0.10 76.2 2.8 4.72 0.86 100 6.78 0.41 100
Cisplatin 1.07 0.02 3.73 0.06 2.87 0.06 4.59 0.27 6.31 0.40 2.74 0.06
a Lung cancer cells.
b Bronchial epithelial cells
c Colorectal cancer cells.
d Colonic epithelial cells.
eMelanoma cells.
f Epidermal cells immortalized.
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globatus RJ2 through homologous recombination (Fig. 4c). As
predicted, the resulting mutant RJ15 did not produce 1-4 as
judged by HPLC-MS analysis (Fig. 4a), confirming that nat-
hyg5 is essential for the production of 1-4.This is a rare, but not
unprecedented (24, 25), example of cooperation to produce a
natural product between a gene cluster and a gene remotely
located on the genome, either isolated or within a different
BGC.
Production of 1–4 by co-expression of nat-hyg5 and nat BGC
genes in J1074
Having shown that nat-hyg5 involves in the production of
1-4, we successfully produced these compounds in a heterolo-
gous host by co-expression of the nat-hyg5 gene and the nat
BGC. We previously established a heterologous system to pro-
duce NAT-A (5) and -F (6) in Streptomyces albus J1074 by
incorporation of a phiC31 integrative plasmid, pRJ4, containing
natA-E genes (Fig. 4, b and d) (2). The metabolite profile of
pRJ4/J1074 reveals no production of 1-4, suggesting that no
functional 3-hydroxybenzoate synthase homolog exists in
J1074. To produce 1-4 in the host of pRJ4/J1074, the nat-hyg5
gene was cloned under the constitutive strong promoter of
ermE* (26) using vector ppYJ10 containing the Streptomyces
replication element derived from pIJ101 (27). The resultant
plasmid pRJ71 and the control ppYJ10 were each introduced
into pRJ4/J1074 through conjugation.HPLC-MS analysis of the
fermentation extract indicated that 1-4 were produced as new
components after introduction of pRJ71 into pRJ4/J1074, in
contrast to the negative controlwith ppYJ10 introduced instead
(Fig. 4b). Interestingly, although the production ratio of 1–4
remained same, the yield level of 1–4 was obviously increased
relative to that of 5 and 6 in the heterologous expression host by
comparing with the parent strain RJ2 (Fig. 4, a and b), implying
that the production of 1-4 could be improved in the future by
overexpression of nat-hyg5 for enhancing the supply of 3-HBA
precursor. Moreover, the co-appearance of C1 hydroxyl and
ketone in 1-4 is likely due to the lower activity of theNAD(P)H-
dependent ketoreductase NatE toward the substrates of NAT
skeleton containing a 3-HBA moiety. This proposal is sup-
ported by the in vitro assay of NatE with compound 1 as sub-
strate (Fig. S7).
In vitro characterization of Nat-hyg5
To investigate directly the enzymatic activity of nat-hyg5, the
gene was overexpressed in Escherichia coli BL21 (DE3), allow-
ing purification of the encodedNat-hyg5 protein to near homo-
geneity. Recombinant Nat-hyg5 with a C-terminal His tag was
estimated to have a molecular mass of 37.6 kDa as determined
by SDS-PAGE analysis (Fig. S8). Upon incubation of choris-
mate (4 mM) with Nat-hyg5 (0.5 M) in Tris-HCl (50 mM, pH
Figure 3. Proposed biosynthetic pathway of 1-4. The 3-HBA generated by Nat-hyg5 from chorismate, the end product of shikimate pathway, could be
accepted as a starter unit to produce1-4by neoantimycinNRPS-PKS, which originally uses 3-FAS as starting precursor to produce5 and6 (2, 9).A, adenylation;
T, thiolation; C, condensation; KR, ketoreductase; KS, ketosynthase; AT, acyltransferase; MT, methyltransferase; ACP, acyl-carrier protein; TE, thioesterase. The
dimethyl extender unit in M4 was confirmed to be generated by the MT domain acting twice upon a malonate unit loaded by the AT domain (9).
Anticancer depsipeptide biosynthesis requires a chorismatase
5512 J. Biol. Chem. (2020) 295(16) 5509–5518
8.0) at 35 °C for 30 min, the expected products 3-HBA and
pyruvate were formed as judged by the HPLC-MS analysis,
whereas no conversion was observed in the control incubation
with boiled Nat-hyg5 (Fig. 5). Chorismate is known to undergo
a background spontaneous decomposition to 4-HBA in Tris-
HCl buffer at 37 °C (28), and in agreement with this, a trace
amount of 4-HBA was detected in the assay with both intact
and boiled Nat-hyg5 (Fig. 5). Chorismatases have been classi-
fied into four subfamilies: CH-I/CH-FkbO, CH-II/CH-Hyg5,
CH-III/CH-XanB2, and CH-IV according to the respective
reaction products (21, 22) (Fig. S5). Based on its determined
enzymatic activity, Nat-hyg5 should be assigned to the
CH-Hyg5/CH-II subfamily (EC 4.1.3.45). Protein sequence
alignment confirmed that the characteristic CH-Hyg5/CH-II
subfamily residues Gly-164, Gly-231, and Cys-318 are all pres-
ent in Nat-hyg5 (Fig. S6).
The steady-state kinetic parameters of the Nat-hyg5–
catalyzed reactionwere determined in a coupled spectrophoto-
metric assay, monitoring the reduction of the pyruvate gener-
ated by chorismatase (29). In the assay, Nat-hyg5 was
demonstrated to be potently active across a broad pH range,
exhibiting kcat values of 0.039–0.176 s1 (S.E., 0.001–0.008)
over the pH range of 6.5–8.5 (Table 2), in contrast to the two
characterized CH-Hyg5/CH-II type chorismatases, Hyg5 (kcat
0.22 s1, pH 7.0) and Cuv10 (kcat 0.11 s1, pH 6.5) derived
respectively from the biosynthetic pathways of the rapamycin
analog BC325 and cuevaene A (14, 15). The Km values of Nat-
hyg5 were calculated in the range of 47–65 M (S.E., 4–8)
(Table 2), compared with the 530 M of Hyg5 and 26 M of
Cuv10 (14, 15). It is worthy of mention that all the kinetic
parameters were calculated based on the substrate concentra-
tion of 50–300M (Fig. S9), and in the lower substrate concen-
tration, no qualified linear value of the enzymatic velocity curve
was obtained in this method. The robust activity of Nat-hyg5
suggests a potential application in synthetic biology to biosyn-
thesize the valuable compounds requiring 3-HBA as precursor.
Target accumulation of 1 and 2 in the engineered J1074
To create a clearer background for specific biosynthesis of
compounds 1-4 in a heterologous host, we set out to generate
an engineered J1074 strain solely providing 3-HBA precursor
and losing the ability of 3-FAS biosynthesis. To this end, a
mutant RJ16 has been generated from J1074 by using aCRISPR-
Cas9 system (see “Materials and methods”). In the mutant, the
genes antH–L, encoding the phenylacetate-CoA oxygenase
complex in 3-FAS biosynthesis (7, 30, 31), were replaced by a
cassette consisting of nat-hyg5 gene and twowell-characterized
strong promoters, A35*p and A26*p (32) (Fig. S10a). The two
Figure 4. The production of 1-4 is identified to be correlated to the function of nat-hyg5 gene located in an unknown type-I PKS BGC. a, HPLC-MS
analysis of the fermentation extract of RJ2 and themutant strain RJ15 generated fromRJ2 by inactivation of nat-hyg5 gene (E325Q). b, HPLC-MS analysis of the
fermentation extract of S. albus J1074 containing either pRJ4 (natA-E) or pRJ4 and pRJ71 (natA-E nat-hyg5). The HPLC-MS data are displayed with the mass
extraction ofm/z 664–722. The stars labeled in the HPLC-MS of RJ2 represent the elution positions of 3 and 4, which can be recognized by using specific mass
extraction (Fig. S3). c and d, the graphical schemes of c and d are corresponding to a and b, respectively, describing the gene organizations and the expected
products of the analyzed strains.
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exogenous promoters were designed to motivate, respectively,
the transcription of nat-hyg5 gene and the antG-antF operon
encoding acyl carrier protein and acyl-CoA ligase required in
the loading stage of antimycin-type NRPS-PKS (Fig. 3) (1, 10).
Afterward, the plasmid pRJ4 containing natA-Ewas introduced
into RJ16 to generate pRJ4/RJ16. According to HPLC-MS anal-
ysis, pRJ4/RJ16 loses ability to produce 5 and 6 but solely accu-
mulates 1 and 2 in a lower level compared with the yield in
pRJ71  pRJ4/J1074 (Fig. S10b). Moreover, the compounds 3
and 4 produced with trance level in pRJ71  pRJ4/J1074 (Fig.
4b) were not detected in pRJ4/RJ16. We speculate that it
might be due to the limit supply of 3-HBA because only one
copy of nat-hyg5 gene is introduced into RJ16. Future pro-
duction optimization for 1-4 could be carried out by either
overexpressing nat-hyg5 in RJ16 or disrupting 3-FAS biosyn-
thesis in RJ2.
Conclusions
We have discovered four new neoantimycin analogs, unanti-
mycin B-E (1-4), attached with unusual 3-HBA moiety instead
of the conserved 3-FAS in antimycin-type depsipeptides. Com-
pound 1-4 showed a similar level of anticancer activities as the
chemotherapeutic drug, cisplatin, in bioactivity assays with
human lung cancer, colorectal cancer, and melanoma cells.
Noticeably, they mostly did not exhibit obvious inhibitory
activities against the corresponding normal cells. Because the
3-FAS group in antimycin A has been identified as the func-
tional group correlatedwith respiratory chain toxicity, we spec-
ulate that the substitution of 3-FAS moiety with 3-HBA may
contribute to the reduced toxicity of 1-4 toward noncancerous
cells. This may be a clue for structure–activity optimization of
the family of natural products. By using site-directed mutagen-
esis and heterologous co-expression, the production of 1-4was
identified to be correlated to the function of a 3-hydroxybenzo-
ate synthase/chorismatase gene, nat-hyg5, associated with an
unknown type I PKS BGC. Biochemical characterization and
protein sequence analysis confirmed that the Nat-hyg5 is a
CH-Hyg5/CH-II type chorismatase showing efficient catalysis
in a broad pH range. Evidently the PKS-NRPS assembly line of
neoantimycin biosynthesis can accept 3-HBA as an alternative
starter unit to produce 1-4, revealing a cross-talk between
unrelated natural product biosynthetic pathways. Finally, spe-
cific accumulation of 1 and 2 is achieved by creating an engi-
neered chassis host, facilitating further optimization to serve
pharmacological study. Thework has expanded the neoantimy-
cin family by discovery of four new analogs with promising
anticancer properties. The elucidation of the biosynthetic path-
way lays a foundation to optimize the compounds yield for
oncotherapy application.
Materials andmethods
Compound purification
The fermentation broth (24 liters) of RJ2, after adjusting the
pH 6 with formic acid, was extracted three times with an equal
volume of ethyl acetate. The combined organic phase was con-
centrated under vacuum to afford 32.7 g of syrup extract, which
was then dissolved in 400 ml of methanol and degreased three
times with 200 ml of hexane. The methanol phase was concen-
trated to 27.6 g and then subjected to vacuum LC on silica gel
(200–300 mesh) and fractionated by using stepwise elution
with dichloromethane-methanol (from 50:1 to 0:1, v/v) to
afford nine fractions, E1–E9. Guided by HPLC-MS analysis, E1
(10.2 g) and E2 (2.0 g) were combined and separated again
through the same vacuumLC columnwith the elution of petro-
leum ether-acetone (5:1 to 0:1, v/v) to give ten fractions, E1A–
E1J. Then E1D, E1E, and E1F were combined as one fraction
(1.5 g) before being separated through an ODS chromatogra-
phy column (YMC-Pack Pro C18 RS, 20  250 mm, 5 m) by
using medium pressure preparative liquid chromatography in
the condition of 15 ml/min, 30–100% acetonitrile/H2O (0.1%
formic acid) in 4 h, and UV210 to obtain nine fractions E1D1–
E1D9. Then E1D7 (63mg) was purified through a semiprepara-
tive column (Waters Xbridge C18, 10  250 mm, 5 m) by
using the HPLC condition of 80% methanol/H2O (0.1% formic
acid), 3 ml/min, and UV210 to afford compound 1 (16.0 mg, tR
20 min). E1D6 (72 mg) was purified through the same semi-
preparative column by using the HPLC condition of 62% ace-
tonitrile/H2O (0.1% formic acid), 3 ml/min, and UV210 to yield
compound 2 (3.6 mg, tR 28 min) and 3 (3.0 mg, tR 34 min).
Figure 5. HPLC-MS analysis of the products generated inNat-hyg5 enzy-
matic assays. The reaction scheme is given at the top. HPLC-MS data are
displayedwith total ion current.Asterisks are used tomark thepeaks detected
in the assay with either intact or boiled Nat-hyg5. The peak at 6.2 min repre-
sents 4-HBA. The two peaks labeled 7 should represent the isomers of choris-
mate, which were detected in a reported chorismatase activity assay (14).
Table 2
The calculated kinetic parameters of Nat-hyg5 in enzymatic assay
pH values of assay buffer
6.5 7.4 8.0 8.5
kcat (103 s1)a 176 8 133 5 84 3 39 1
Km (M)a 47 8 65 8 54 6 50 4
kcat/Km (103 s1 M1)b 3.8 2.1 1.6 0.8
a The values shown are the means S.E. calculated by Prism7 across three
replicates.
b The values shown are the means of three replicates.
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Finally, E1D5 (4mg) was purified through an analytical column
(Phenomenex C18, 4.6  250 mm, 5 m) by using the HPLC
condition of 56% acetonitrile/H2O (0.1% formic acid), 0.8
ml/min, and UV210 to produce compound 4 (0.6 mg, tR 37
min). Moreover, 0.9 mg more of compound 4 was isolated
from another batch of 24 liters of fermentation for bioactiv-
ity assay.
Anticancer and toxicity activities assay
Anticancer activities were evaluated by using human lung
cancer cells PC9, human colorectal cancer cells Sw620, and
humanmelanoma cells A375. Toxicity study was conducted by
using three types of normal cells, 16HBE (an immortalized
human bronchial epithelial cells), NCM460 (a normal human
colonmucosal epithelial cell line), andHaCaT (a spontaneously
immortalized keratinocyte cell line from adult human skin). All
the cell lines were obtained from the Shanghai Institute of Cell
Biology, Chinese Academy of Sciences. The cell cultivation
media (Gibco)were supplementedwith 10% fetal bovine serum,
100 units/ml penicillin, and 100 g/ml streptomycin. The cells
were maintained in a humidified atmosphere with 5% CO2 at
37 °C. Half-maximal inhibitory concentration (IC50) was deter-
mined by a CCK8 assay (Dojindo, Tokyo, Japan). Briefly, the
cells were seeded in 96-well plates at a density of 3 103 cells/
well and incubated for 24 h at 37 °C. Then the cells were treated
with various concentrations of compound and incubated for
72 h. Afterward, 10 l of CCK8 reagent was added to each well
before a further incubation for 0.5–4.0 h at 37 °C. Finally, the
absorbance of each well in the 96-well plate was measured at
450 nm using microplate reader.
Deletion of the congE gene
To generate amutant strain producing compounds 1–4with
clearer background, the congE gene putatively essential to con-
globatin biosynthesis (19) was selected to be removed in S. con-
globatus by an in-frame deletion. To construct a gene cassette
for homologous recombination, primers CongE-L-S and
CongE-L-A andprimersCongE-R-S andCongE-R-A (Table S1)
were used to amplify a 1736-bp left arm and a 1788-bp right
arm, respectively. The two PCR fragments were assembled, by
Gibson assembly (33), with the E. coli–Streptomyces shuttle
plasmid pRJ2 linearized with XbaI and EcoRI (2). The resulting
plasmid pRJ3 was used to transform S. conglobatus via conjuga-
tion from E. coli ET12567 with the helper plasmid pUZ8002.
The target mutant was screened by using colony PCR with the
primers congE-TF and congE-TR (Table S1) from the hygro-
mycin-sensitive colonies prepared after two rounds of propa-
gation on SFM plates without antibiotics present. The PCR
product was sequenced to confirm the identity of the target
mutant designated as RJ2.
Site-directedmutation of nat-hyg5
The conserved active site residue E325 in the nat-hyg5–
encoded enzyme (Fig. S6) wasmutated to Gln-325 to inactivate
the gene in situ. To construct the required gene cassette for
homologous recombination, primers Lhyg5-S and Lhyg5-A
and primers Rhyg5-S and Rhyg5-A (Table S1) were used to
amplify a 1212-bp left arm and a 1472-bp right arm from the
genomic DNA of RJ2, respectively. The two PCR fragments
were assembled, by Gibson assembly (33), with pRJ2 linear-
lized with XbaI and EcoRI (2). The resulting plasmid pRJ90
was used to transform RJ2 via conjugation. The target
mutant was screened by the same way as above with the
primers Hg-S1 and Hg-A1 (Table S1). The target mutant was
further confirmed by sequencing of the PCR product and
designated as RJ15.
Co-expression of nat-hyg5 and natA-E in J1074
Thenat-hyg5genewas amplified fromthegenomicDNAofRJ2
with the primers Hyg5-S and Hyg5-A (Table S1) and was cloned
under the strong constitutive promoter of ermE* in ppYJ10,which
contains a Streptomyces replication element derived from pIJ101
(27). Through conjugation, the resultant plasmid pRJ71 was used
to transform the strain pRJ4/J1074, which produces compounds 5
and 6 with genes natA-E cloned in the plasmid pRJ4 (2). The
resultant strain pRJ71  pRJ4/J1074, which is resistant to both
thiostrepton and apramycin, was identified from among the
exconjugants by colony PCR with the primers C-ppYJ10-S and
C-ppYJ10-A (Table S1).
Engineering of J1074 as a host to specific accumulation of 1
and 2
The antH-L genes of antimycin BGC in J1074 were designed to
be replaced with a hyg5 cassette (nat-hyg5_A35*p_ap(r)_A26*p)
containing the nat-hyg5 gene, two strong promoters A35*p and
A26*p (32), and an ampicillin-resistant gene (ap(r)) (see related
primers in Table S1). The nat-hyg5 gene was amplified from
pRJ71. The fragment of A35*p_ap(r)_A26*p was amplified from
ppYJ10 by using three rounds of PCR. The two homologous arms
were amplified from the genomic DNA of J1074. By using Gibson
assembly, the above four PCR products were assembled into the
hyg5 cassette based on a vector fragment, pUC19 fragment1
amplified from ppYJ10, which contains E. coli replication. The
hyg5 cassette was digested with HindIII and religated to pUC19
fragment2, which is the extension version of pUC19 fragment 1
with the25/29-bp franking sequences identical to theHindIII/StuI
end of pMWcas9 (34). After EcoRI and XbaI digestion, the
extendedhyg5cassettewas recoveredand introduced into theStuI
and HindIII sites of the pMWcas9 derivative, which was loaded
with a sgRNA sequence targeting the ORF region of antH in anti-
mycin BGC. The resultant plasmid pRJ92 was introduced into
J1074 by conjugation, and the target mutant was screened by fol-
lowing a reported procedure (34). The resultant mutant RJ16 was
further confirmed by sequencing of the PCR products.
Nat-hyg5 protein expression and purification
For protein expression of Nat-hyg5 with a C-terminal His
tag, the gene nat-hyg5was amplified from pRJ71 with the prim-
ers hyg5-F and hyg5-A (Table S1), and the PCR fragment was
introduced into the NdeI and XhoI sites of pET29a by Gibson
assembly. The resultant plasmid pRJ89 was used to transform
E. coli BL21 (DE3) plysS for protein expression. The overnight
culture (1 ml) of the target transformant was transferred into
0.5-liter LB medium containing kanamycin (50 g/ml) (37 °C,
220 rpm). Isopropyl--D-thiogalactopyranoside (0.2 mM) was
added to the culture once theA600 reached 0.6–0.8, followed by
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further cultivation for 15 h at 22 °C. The cells were recovered by
centrifugation (11,325 g, 5 min) and resuspended in buffer A
(50mMTris-HCl, 300mMNaCl, pH 7.2) for sonication. The cell
lysate was centrifuged (34,925  g, 25 min), and the superna-
tant was passed through a 0.22-m filter before loading onto a
His-Bind affinity column (1-ml bed volume). The target pro-
teins were eluted by stepwise increases of the concentration of
imidazole (10 to 500 mM). Concentration and buffer exchang-
ing of the protein was done by using Amicon Ultra-4 concen-
trators (Millipore, 10-kDa cutoff). Protein-containing fractions
of the eluate were analyzed using Bis-Tris gel SDS-PAGE
(4–12%). Protein concentrations were measured by using a
NanoDrop 1000 spectrophotometer.
Nat-hyg5 enzyme assays
The enzymatic assay for qualitative analysis was carried out
in 100 l of Tris-HCl buffer (50 mM, pH 8.0) containing 4 mM
chorismate (Sigma) and 0.5MNat-hyg5 at 35 °C for 30min. A
negative control consisted of Nat-hyg5 preboiled at 100 °C for
10 min. The reactions were stopped by adding 400 l of aceto-
nitrile, and the solution was centrifuged at maximum speed for
5 min before taking 20 l of the supernatant for HPLC-MS
analysis.
The kinetic parameters of the Nat-hyg5–catalyzed reaction
were determined by lactate dehydrogenase (LDH)–coupled
assay (29) in 50 mM Tris-HCl buffer at the pH values of 6.5, 7.4,
8.0, and 8.5 respectively. The assay was carried out in a 96-well
plate andmonitored at 340 nmby SpectraMax 190 plate reader.
First, chorismate with a concentration between 50 and 300 M
was preincubated with 2.5 units/ml LDH (Sigma) and 0.5 mM
NADHuntil the absorption at 340 nmwas stable, to ensure that
all extraneous pyruvate was converted into lactate by LDH in
the consumption ofNADH. Subsequently, Nat-hyg5was added
to the system to 0.5 M concentration to monitor the rate of
decline in absorption at 340 nm over 5min, which reflected the
consumption rate of the pyruvate generated by Nat-hyg5 from
chorismate. All the reactions were performed in triplicate.
Finally, the enzyme kinetic parameters were calculated by fit-
ting the Michaelis–Menten model in the Prism 7 (GraphPad,
SanDiego,CA). The kcat andKm values are obtained asmeans
S.E. calculated by Prism7. The kcat/Km values were acquired as
the means of three replicates.
Media, culture conditions, and strains
TSBY medium (3% tryptone soy broth, 0.5% yeast extract,
10.3% sucrose) was used producemycelium. SFM agarmedium
(2% soya flour, 2% D-mannitol, 2% agar, 10mMMgCl2) was used
for manipulation of conjugation and mutant screening. For
NATs production in RJ2, the seedmedium (SGCc) consisted of
3% soybean flour, 5% glucose, 0.5% CaCO3, 5 mg/liter
CoCl26H2O, and 0.2% (v/v) anti-foam, and the production
medium (SGC) was the SGCc recipe omitting CoCl26H2O. For
the fermentation of J1074-derivative strains, the seed medium
was TSBY, and the production medium (SMG) consisted of 3%
soya flour, 1%malt extract, 0.3%CaCO3, 0.5% glucose, and 0.1%
(v/v) antifoam.
Fermentation was carried out by inoculating 150 ml of
medium in a 500-ml conical flask fitted with a metal spring,
with 10% (v/v) inoculation of 3-day seed culture and then incu-
bating at 30 °C, 220 rpm for 5 days. For small scale fermenta-
tion, 50ml of medium in a 250-ml conical flask was used. E. coli
strains were grown in Luria–Bertani (LB) broth (1% tryptone,
0.5% yeast extract, 0.5% NaCl) or LB agar (1.5% agar) at 37 °C
with the corresponding antibiotics added.
S. conglobatusRJ2was theWTproducer of compounds 1–6.
S. albus J1074 served as a heterologous host. E. coliDH10B was
used for plasmid construction. E. coli ET12567 containing
helper plasmid pUZ8002 was used as a transitional host for
introducing target plasmid into Streptomyces strains. The
E. coli BL21 (DE3) plysS strain was used as the host for protein
expression.
DNAmanipulation
The oligonucleotides used in this work are summarized in
Table S1. Restriction endonucleases and T4 DNA ligase were
purchased from New England Biolabs. Gibson assembly solu-
tion was the U-Clone master mix kit (Evomic Science, Sunny-
vale, CA). Chemicals were purchased from Sigma–Aldrich.
Plasmid DNA was isolated from an overnight culture using a
plasmid mini kit (Shanghai Generay Biotech). The PCR tem-
plate of genomic DNA was prepared by using 10% Chelex 100
resin (Bio-Rad) solution. PCR amplifications were carried out
using Phusion High-Fidelity PCR Master Mix (New England
Biolabs) for cloning, or 2 FastTaqMasterMix (Shanghai Bio-
root Biotech) for screening.
Analytical methods
The HPLC-MS analysis was performed on a Waters HPLC
coupled with a Waters Acquity QDa detector. The analytical
HPLC was fitted with a Waters Xbridge C18 column (250
mm  4.6 mm, 5 m). The solvent system consisted of aceto-
nitrile and H2O (0.1% formic acid, v/v). The samples were
eluted isocratically at a flow rate 0.8 ml min1 with 75% of
acetonitrile over 20 min. The mass spectrometer was run in
either positive or negative ionization mode, scanning fromm/z
200 to 1250 with capillary (0.80 kV), cone (15.00 V), and source
temperature (120 °C). The high-resolution TOF–electrospray
ionization–MS spectrawere acquiredwith aUltra Performance
Liquid Chromatography (UPLC)Waters XeVO G2-XS Q TOF
mass spectrometer. The mass spectrometer was run in positive
ionization mode, scanning fromm/z 100 to 1200. The MS/MS
was carried out with a collision energy ramp of 30–40 eV, a
scan time of 0.200 s, and an interscan time of 0.014 s. TheUPLC
was fitted with a Waters Acquity UPLC BEH C18 column (2.1
mm  50 mm, 1.7 m). A solvent system of acetonitrile and
H2O (0.1% formic acid, v/v) was used for isocratic sample elu-
tion with 60% acetonitrile over 5 min at a flow rate of 0.4 ml
min1. NMR spectra were recorded on an Agilent DD2 600
MHz NMR spectrometer, using DMSO-d6 as solvent.
Data availability statement
Nucleotide and protein sequences of the type-I PKS BGC
containing nat-hyg5 gene have been deposited in the NCBI
GenBankTM under accession number MN158725. All other
data are contained within the manuscript.
Anticancer depsipeptide biosynthesis requires a chorismatase
5516 J. Biol. Chem. (2020) 295(16) 5509–5518
Author contributions—Y. S., F. S., and S.-P. W. data curation; Y. S.
formal analysis; Y. S., F. S., L. Z., Y. C., H. Z., and S.-P. W. investiga-
tion; Y. S., H. Z., and S.-P. W. methodology; Y. S. and Y. Z. writing-
original draft; F. S., S.-P. W., Y. Z., and H.-W. L. funding acquisition;
W.-H. J., P. F. L., and Y. Z. writing-review and editing; P. F. L., Y. Z.,
and H.-W. L. resources; Y. Z. conceptualization; Y. Z. supervision;
Y. Z. project administration.
Acknowledgment—We thank Prof. Xudong Qu from Shanghai Jiao
Tong University for kind suggestions and providing pMWcas9.
References
1. Liu, J., Zhu, X., Kim, S. J., and Zhang,W. (2016) Antimycin-type depsipep-
tides: discovery, biosynthesis, chemical synthesis, and bioactivities. Nat.
Prod. Rep. 33, 1146–1165 CrossRef Medline
2. Zhou, Y., Lin, X., Williams, S. R., Liu, L., Shen, Y., Wang, S. P., Sun, F., Xu,
S., Deng,H., Leadlay, P. F., and Lin,H.W. (2018)Directed accumulation of
anticancer depsipeptides by characterization of neoantimycins biosyn-
thetic pathway and anNADPH-dependent reductase.ACSChem. Biol.13,
2153–2160 CrossRef Medline
3. Salim, A. A., Cho, K. J., Tan, L., Quezada, M., Lacey, E., Hancock, J. F., and
Capon, R. J. (2014) Rare Streptomyces N-formyl amino-salicylamides in-
hibit oncogenic K-Ras. Org Lett. 16, 5036–5039 CrossRef Medline
4. Izumikawa, M., Ueda, J. Y., Chijiwa, S., Takagi, M., and Shin-ya, K. (2007)
Novel GRP78 molecular chaperone expression down-regulators JBIR-04
and -05 isolated from Streptomyces violaceoniger. J. Antibiot. (Tokyo) 60,
640–644 CrossRef Medline
5. Manaviazar, S., Nockemann, P., and Hale, K. J. (2016) Total synthesis of
the GRP78-downregulatory macrolide ()-prunustatin A, the immuno-
suppressant ()-SW-163A, and a JBIR-04 diastereoisomer that confirms
JBIR-04 has nonidentical stereochemistry to ()-prunustatin A.Org. Lett.
18, 2902–2905 CrossRef Medline
6. Vanner, S. A., Li, X., Zvanych, R., Torchia, J., Sang, J., Andrews, D.W., and
Magarvey, N. A. (2013) Chemical and biosynthetic evolution of the anti-
mycin-type depsipeptides.Mol. Biosyst. 9, 2712–2719 CrossRef Medline
7. Liu, J., Zhu, X., Seipke, R. F., and Zhang, W. (2015) Biosynthesis of anti-
mycins with a reconstituted 3-formamidosalicylate pharmacophore in
Escherichia coli. ACS Synth. Biol. 4, 559–565 CrossRef Medline
8. Schoenian, I., Paetz, C., Dickschat, J. S., Aigle, B., Leblond, P., and Spiteller,
D. (2012) An unprecedented 1,2-shift in the biosynthesis of the 3-amin-
osalicylate moiety of antimycins. Chembiochem. 13, 769–773 CrossRef
Medline
9. Skyrud,W., Liu, J., Thankachan, D., Cabrera, M., Seipke, R. F., and Zhang,
W. (2018) Biosynthesis of the 15-membered ring depsipeptide neoantimy-
cin. ACS Chem. Biol. 13, 1398–1406 CrossRef Medline
10. Awakawa, T., Fujioka, T., Zhang, L., Hoshino, S., Hu, Z., Hashimoto, J.,
Kozone, I., Ikeda, H., Shin-Ya, K., Liu, W., and Abe, I. (2018) Reprogram-
ming of the antimycin NRPS-PKS assembly lines inspired by gene evolu-
tion. Nat. Commun. 9, 3534 CrossRef Medline
11. Lin, X., Zhou, Y., Liu, L., Zhu, H., Chen, Y., Wang, S., Sun, F., Chai, L., Liu,
B., Xu, S., and Lin, H.-W. (2019) Compound discovery and structure-
activity relationship study of neoantimycins against drug-resistant cancer
cells. Front. Chem. 7, 481 CrossRef Medline
12. Huang, L. S., Cobessi, D., Tung, E. Y., and Berry, E. A. (2005) Binding of the
respiratory chain inhibitor antimycin to the mitochondrial bc1 complex: a
new crystal structure reveals an altered intramolecular hydrogen-bonding
pattern. J. Mol. Biol. 351, 573–597 CrossRef Medline
13. Lim, C. L., Nogawa, T., Okano, A., Futamura, Y., Kawatani,M., Takahashi,
S., and Ibrahim, D. (2016), and Osada, H. Unantimycin A, a new neoanti-
mycin analog isolated from a microbial metabolite fraction library. J. An-
tibiot. (Tokyo) 69, 456–458 Medline
14. Andexer, J. N., Kendrew, S. G., Nur-e Alam, M., Lazos, O., Foster, T. A.,
Zimmermann, A. S.,Warneck, T. D., Suthar, D., Coates, N. J., Koehn, F. E.,
Skotnicki, J. S., Carter, G. T., Gregory,M. A.,Martin, C. J., Moss, S. J., et al.
(2011) Biosynthesis of the immunosuppressants FK506, FK520, and rapa-
mycin involves a previously undescribed family of enzymes acting on cho-
rismate. Proc. Natl. Acad. Sci. U.S.A. 108, 4776–4781; Correction (2019)
Proc. Natl. Acad. Sci. U.S.A. 116, 8080 Medline
15. Jiang, Y., Wang, H., Lu, C., Ding, Y., Li, Y., and Shen, Y. (2013) Identifica-
tion and characterization of the cuevaene A biosynthetic gene cluster in
Streptomyces sp. LZ35. Chembiochem. 14, 1468–1475 CrossRef Medline
16. Zhou, L., Wang, J. Y., Wang, J., Wu, J., Poplawsky, A., Lin, S., Zhu, B.,
Chang, C., Zhou, T., Zhang, L. H., and He, Y. W. (2013) The diffusible
factor synthase XanB2 is a bifunctional chorismatase that links the shiki-
mate pathway to ubiquinone and xanthomonadins biosynthetic pathways.
Mol. Microbiol. 87, 80–93 CrossRef Medline
17. Cao, X. Q., Wang, J. Y., Zhou, L., Chen, B., Jin, Y., and He, Y. W. (2018)
Biosynthesis of the yellow xanthomonadin pigments involves an ATP-de-
pendent 3-hydroxybenzoic acid: acyl carrier protein ligase and an unusual
type II polyketide synthase pathway.Mol.Microbiol. 110, 16–32CrossRef
Medline
18. Hayashi, Y., Matsuura, N., Toshima, H., Itoh, N., Ishikawa, J., Mikami, Y.,
and Dairi, T. (2008) Cloning of the gene cluster responsible for the bio-
synthesis of Brasilicardin A, a unique diterpenoid. J. Antibiot. (Tokyo) 61,
164–174 CrossRefMedline
19. Zhou, Y., Murphy, A. C., Samborskyy, M., Prediger, P., Dias, L. C., and
Leadlay, P. F. (2015) Iterativemechanismofmacrodiolide formation in the
anticancer compound conglobatin. Chem. Biol. 22, 745–754 CrossRef
Medline
20. Miyoshi, H., Tokutake, N., Imaeda, Y., Akagi, T., and Iwamura, H. (1995)
A model of antimycin A binding based on structure-activity studies of
synthetic antimycin A analogues. Biochim. Biophys. Acta. 1229, 149–154
CrossRef Medline
21. Hubrich, F., Juneja, P.,Müller,M., Diederichs, K.,Welte,W., andAndexer,
J. N. (2015) Chorismatase mechanisms reveal fundamentally different
types of reaction in a single conserved protein fold. J. Am. Chem. Soc. 137,
11032–11037 CrossRef Medline
22. Grüninger, M. J., Buchholz, P. C. F., Mordhorst, S., Strack, P., Müller, M.,
Hubrich, F., Pleiss, J., and Andexer, J. N. (2019) Chorismatases: the family
is growing. Org. Biomol. Chem. 17, 2092–2098 CrossRef Medline
23. Gregory, M. A., Petkovic, H., Lill, R. E., Moss, S. J., Wilkinson, B., Gaisser,
S., Leadlay, P. F., and Sheridan, R. M. (2005) Mutasynthesis of rapamycin
analogues through the manipulation of a gene governing starter unit bio-
synthesis. Angew. Chem. Int. Ed. Engl. 44, 4757–4760 CrossRef Medline
24. Lazos, O., Tosin, M., Slusarczyk, A. L., Boakes, S., Cortés, J., Sidebottom,
P. J., and Leadlay, P. F. (2010) Biosynthesis of the putative siderophore
erythrochelin requires unprecedented crosstalk between separate nonri-
bosomal peptide gene clusters.ChemBiol. 17, 160–173CrossRefMedline
25. Li, S., Guo, J., Reva, A., Huang, F., Xiong, B., Liu, Y., Deng, Z., Leadlay, P. F.,
and Sun, Y. (2018) Methyltransferases of gentamicin biosynthesis. Proc.
Natl. Acad. Sci. U.S.A. 115, 1340–1345 CrossRef Medline
26. Wilkinson, C. J., Hughes-Thomas, Z. A., Martin, C. J., Böhm, I., Mi-
ronenko, T., Deacon, M., Wheatcroft, M., Wirtz, G., Staunton, J., and
Leadlay, P. F. (2002) Increasing the efficiency of heterologous promoters
in actinomycetes. J. Mol. Microbiol. Biotechnol. 4, 417–426 Medline
27. Sun, Y., He, X., Liang, J., Zhou, X., and Deng, Z. (2009) Analysis of func-
tions in plasmid pHZ1358 influencing its genetic and structural stability in
Streptomyces lividans 1326. Appl. Microbiol. Biotechnol. 82, 303–310
CrossRef Medline
28. Siebert, M., Bechthold, A., Melzer, M., May, U., Berger, U., Schröder, G.,
Schröder, J., Severin, K., and Heide, L. (1992) Ubiquinone biosynthesis:
cloning of the genes coding for chorismate pyruvate-lyase and 4-hydroxy-
benzoate octaprenyl transferase from Escherichia coli. FEBS Lett. 307,
347–350 CrossRef Medline
29. Rusnak, F., Liu, J., Quinn, N., Berchtold, G. A., and Walsh, C. T. (1990)
Subcloning of the enterobactin biosynthetic gene entB: expression, puri-
fication, characterization, and substrate specificity of isochorismatase.
Biochemistry 29, 1425–1435 CrossRef Medline
30. Yan, Y., Zhang, L., Ito, T., Qu, X., Asakawa, Y., Awakawa, T., Abe, I., and
Liu, W. (2012) Biosynthetic pathway for high structural diversity of a
common dilactone core in antimycin production. Org. Lett. 14,
4142–4145 CrossRef Medline
Anticancer depsipeptide biosynthesis requires a chorismatase
J. Biol. Chem. (2020) 295(16) 5509–5518 5517
31. Sandy,M., Rui, Z., Gallagher, J., andZhang,W. (2012) Enzymatic synthesis
of dilactone scaffold of antimycins. ACS Chem. Biol. 7, 1956–1961
CrossRef Medline
32. Ji, C.H., Kim, J. P., andKang,H. S. (2018) Library of synthetic Streptomyces
regulatory sequences for use in promoter engineering of natural product
biosynthetic gene clusters. ACS Synth. Biol. 7, 1946–1955 CrossRef
Medline
33. Gibson,D.G., Young, L., Chuang, R. Y., Venter, J. C., Hutchison, C.A., 3rd,
and Smith, H. O. (2009) Enzymatic assembly of DNA molecules up to
several hundred kilobases. Nat. Methods 6, 343–345 CrossRef Medline
34. Mo, J., Wang, S., Zhang, W., Li, C., Deng, Z., Zhang, L., and Qu, X. (2019)
Efficient editing DNA regions with high sequence identity in actinomyc-
etal genomes by a CRISPR-Cas9 system. Synth. Syst. Biotechnol. 4, 86–91
CrossRef Medline
Anticancer depsipeptide biosynthesis requires a chorismatase
5518 J. Biol. Chem. (2020) 295(16) 5509–5518
